Summary & Overview
CPT 0530U: LiquidHallmark® ctDNA NGS Assay with Interpretive Report
CPT code 0530U designates LiquidHallmark®, a proprietary next-generation sequencing (NGS) assay performed by Lucence Health Inc. that analyzes circulating tumor DNA (ctDNA) in plasma to detect mutations in 77 genes, identify eight gene fusions, and evaluate microsatellite instability and tumor mutation burden, accompanied by an interpretive report with therapy recommendations. As a PLA code, 0530U is specific to a single manufacturer’s test and is used nationally to capture use of this distinct genomic assay in oncology care.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical utility and coding context, typical sites of service, and payer coverage considerations. The publication summarizes common modifiers used with laboratory services, highlights where data was available or not, and outlines what benchmarks and policy updates to watch for with PLA codes.
The analysis provides clinical context for when a ctDNA NGS assay with comprehensive genomic profiling and interpretive guidance is requested, and it identifies areas where payers commonly apply medical necessity criteria or prior authorization for advanced molecular tests. Data not available in the input is noted where applicable; the content focuses on national implications rather than state-specific policies.
Billing Code Overview
CPT code 0530U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the LiquidHallmark® test from Lucence Health Inc. The test analyzes circulating tumor DNA (ctDNA) in plasma using next-generation sequencing (NGS) to detect mutations across 77 genes, identify eight gene fusions, and assess microsatellite instability (MSI) and tumor mutation burden (TMB). The service includes an interpretive report with therapy recommendations based on the genomic findings.
Service type: Laboratory — circulating tumor DNA (ctDNA) NGS assay with genomic interpretation and therapeutic guidance
Typical site of service: Clinical laboratory or independent diagnostic testing facility (specimen collected in outpatient or hospital settings and processed in a central lab)
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of metastatic non–small cell lung cancer (NSCLC) presents for evaluation after progression on first-line targeted therapy. The oncology team orders a plasma-based circulating tumor DNA (ctDNA) assay, LiquidHallmark® (0530U), to identify actionable somatic mutations, gene fusions, microsatellite instability (MSI), and tumor mutation burden (TMB) to guide next-line systemic therapy and clinical trial eligibility. A peripheral blood draw is collected in an appropriate cell-free DNA tube in the outpatient oncology clinic or an ambulatory phlebotomy center. The sample is shipped to Lucence Health Inc. per the manufacturer’s specimen handling instructions. Results include an interpretive report with detected variants, fusion calls, MSI and TMB status, and therapy recommendations that the treating medical oncologist reviews during a follow-up visit or tumor board to inform systemic treatment selection or referral for targeted therapy or immunotherapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier — not commonly appended; use when no other modifier applies | Rarely used; report when service has no specific modifier requirement |
22 | Increased procedural services | Use when additional work or complexity was required beyond the typical laboratory analytic and interpretive effort and documentation supports increased work
26 | Professional component | Use if reporting only the professional (interpretive) component when separated billing is allowed and the performing lab/provider bills only interpretation
52 | Reduced services | Use when the test was partially performed or a reduced analytic panel was completed and documented
53 | Discontinued procedure | Use if specimen processing or testing was begun but discontinued for documented clinical or technical reasons
TC | Technical component | Use when billing only the technical component (laboratory performance of the assay) and the performing laboratory bills technical services
59 | Distinct procedural service | Use when another unrelated procedure or service on the same date requires distinct reporting (apply only when distinct and supported)
76 | Repeat procedure by same provider | Use when the assay is repeated the same day by the same laboratory for documented reasons
77 | Repeat procedure by another provider | Use when the assay is repeated the same day by a different laboratory/provider
91 | Repeat clinical diagnostic laboratory test | Use when same test is repeated on a subsequent specimen to confirm results
| Taxonomy Code | Specialty | Notes |
|---|---|---|
208000000X | Hematology & Oncology | Ordering and interpreting specialists for ctDNA testing and therapy selection |
208D00000X | Medical Oncology | Primary users of comprehensive ctDNA reports to guide systemic therapy choices
207Q00000X | Pathology | Molecular pathology specialists responsible for result interpretation and reporting quality
207L00000X | Clinical Molecular Genetics | Laboratory directors and molecular diagnostic specialists overseeing NGS assay performance
363L00000X | Laboratory — Independent Diagnostic Testing Facility | Facilities that may perform the technical component and bill the technical component
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung | Common diagnosis for which comprehensive ctDNA NGS is ordered to identify actionable mutations in metastatic lung cancer |
C78.00 | Secondary malignant neoplasm of unspecified lung | Reflects metastatic disease where ctDNA testing can assist in identifying targetable alterations when tissue biopsy is limited
C80.1 | Malignant (primary) neoplasm, multiple sites | Used when widespread metastatic disease prompts broad molecular profiling via plasma ctDNA
Z85.118 | Personal history of other malignant neoplasm of bronchus and lung | Surveillance or recurrence assessment where ctDNA may be utilized to detect molecular relapse
D47.Z2 | Monoclonal gammopathy of undetermined significance (MGUS) — example of non-solid tumor condition | Note: ctDNA assays are primarily for solid tumors; inclusion here represents other hematologic contexts where liquid assays differ
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
80053 | Comprehensive metabolic panel | Common pre-treatment laboratory evaluation performed alongside ctDNA testing to assess organ function prior to therapy changes |
36415 | Collection of venous blood by venipuncture | The standard phlebotomy procedure used to obtain the plasma specimen for the LiquidHallmark® ctDNA assay
88361 | Immunohistochemistry, per slide; interpretation and report | Tumor tissue testing that may be complementary to ctDNA results for biomarker confirmation when tissue is available
81479 | Unlisted molecular pathology procedure | Historically used for novel molecular tests prior to a PLA code; related conceptually but 0530U is the PLA-specific code for LiquidHallmark®
0042U | Molecular cytogenetics or other PLA codes (example) | Other proprietary laboratory analyses that may be ordered in parallel for genomic profiling or when differing panels are required